Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

44806 ARTÍCULOS , VIENDO DEL 541 AL 555

The Role of cGAS-STING-Driven PANoptosis in Neurodegenerative Diseases and Therapeutic Prospects

Hou X, Yu W.

Cells. 2026 Sep 9;15(18):1631. doi: 10.3390/cells15181631.

Hydrogen selenide and selenium donors: From Gasotransmitter biology to precision Neurotherapeutics

Liu X, Du T, Gu Q, Zhang Z, Hui L, Tao L, Shan H, Chen X, Zhang M.

Cell Signal. 2026 Sep;145:112609. doi: 10.1016/j.cellsig.2026.112609. Epub 2026 May 18.

Regenerating smell in neurodegenerative disease -translating theory into therapy

Di Stadio A, Brenner MJ, De Luca P, D'Ascanio L, Patel ZM.

Eur Arch Otorhinolaryngol. 2026 Sep;283(9):6103-6108. doi: 10.1007/s00405-026-10279-9. Epub 2026 May 21.

Qihuang Needle Therapy for Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial

Peng W, Zhao R, Huang Z, Zhou J, Liu Y, Liu Z, Li X, Deng J, Hong X, Chen Y, Wang N, Chen Z.

Mov Disord. 2026 Aug;41(8):2051-2061. doi: 10.1002/mds.70343. Epub 2026 May 9.

Deep Brain Stimulation of the Posterior Subthalamic Area and the Subthalamic Nucleus in Tremor-Dominant Parkinson's Disease: A Randomized, Crossover Trial

Lin Z, Zeng Z, Pan Y, Huang P, Tan Y, Zhang C, Sun B, Li D.

Mov Disord. 2026 Sep;41(9):2375-2385. doi: 10.1002/mds.70363. Epub 2026 May 24.

Transcranial Pulse Stimulation Enhances Dexterity in Parkinson's Disease: A Randomized Sham-Controlled Trial

Matt E, Plischek N, Mitterwallner M, Radjenovic S, Weber A, Domitner A, Dörl G, Zettl A, Osou S, Leitgeb A, Santer A, Winkler V, Mandelburger J, Zach H, Beisteiner R.

Mov Disord. 2026 Sep;41(9):2386-2398. doi: 10.1002/mds.70365. Epub 2026 Jun 1.

Multiple system atrophy-derived α-synuclein fibrils are more potent and display oligodendrocyte cell tropism compared to Parkinson's disease-derived fibrils

Laursen AS, Willén K, Fenyi A, Volbracht C, Dalgaard LT, Aznar S, Melki R, Fog K, Sotty F.

Neurobiol Dis. 2026 Oct 1;228:107575. doi: 10.1016/j.nbd.2026.107575. Epub 2026 Aug 14.

Observations on an Open-Label Phase 1/2 Dopamine Gene Therapy Trial (OXB-102/Axo-Lenti-PD) in People with Parkinson's Disease

Rowe S, Evans A, Kayhanian S, Buttery PC, Morris R, Andresen K, Sherlock L, Hewitt S, Nakornchai T, Hariz M, Mitrophanous K, Zrinzo L, Appleby M, Woodgate P, Maru S, Limousin P, Girges C, Foltynie T, Palfi S, Barker RA.

Mov Disord. 2026 Sep;41(9):2490-2495. doi: 10.1002/mds.70378. Epub 2026 May 28.

Voice disturbances in Parkinson's disease and essential tremor: A cross-sectional acoustic comparison

Gasca-Salas C, Montero Pizarro OG, Šimek M, Jiménez-Castellanos T, Trompeta C, Del Toro-Pérez C, Máñez J, Ruiz-Yanzi A, Matarazzo M, Martínez-Fernández R, Sanabria J, Obika S, Natera-Villalba E, Rusz J.

Parkinsonism Relat Disord. 2026 Sep;150:108423. doi: 10.1016/j.parkreldis.2026.108423. Epub 2026 Jul 9.

A paradoxical plus for Parkinson's in UK's new 'generational smoking ban'

Schwarzschild MA, Macklin EA, Morain SR, Bjornevik K, Olsen AL, Chen X, Gomperts SN, Dorsey ER, Proitsi P, Noyce AJ, Darweesh SKL, Bloem BR.

J Parkinsons Dis. 2026 Sep;16(6):1071-1073. doi: 10.1177/1877718X261469373. Epub 2026 Jul 18.

One-Year Substantia Nigra R2* Changes across Parkinson's Disease Stages

Coussediere C, Pereira B, Devos D, Lehéricy S, Peran P, Durand E, Chassain C, Houeto JL, Benatru I, Colin O, Rascol O, Ory-Magne F, Brefel-Courbon C, Maindreville AD, Vidailhet M, Corvol JC, Frismand S, Schmitt E, Defebvre L, Carriere N, Meissner WG, Boraud T, Remy P, Moro E, Thobois S, Geny C, Bonny JM, Durif F, Marques A; MPI‐R2* study group.

Mov Disord. 2026 Aug;41(8):2117-2132. doi: 10.1002/mds.70331. Epub 2026 Apr 27.

Blue light therapy delivered through light glasses improves sleep quality and daytime sleepiness in Parkinson's disease: A randomized trial

Śmiłowska K, de Vries NM, Bloem BR, van Wamelen DJ.

J Parkinsons Dis. 2026 Sep;16(6):1201-1210. doi: 10.1177/1877718X261468544. Epub 2026 Aug 6.

GBA1 variants and dopaminergic imaging in essential tremor with atypical features: A comparative study with Parkinson's disease

Suoranta M, Kytövuori L, Haataja E, Myller E, Jaakkola E, Noponen T, Eklund M, Nuuttila S, Joutsa J, Murtomäki K, Mertsalmi T, Levo R, Pitkonen M, Scheperjans F, Vahlberg T, Kaasinen V, Martikainen MH.

Parkinsonism Relat Disord. 2026 Sep;150:108410. doi: 10.1016/j.parkreldis.2026.108410. Epub 2026 Jul 6.

Psychomotor retardation and risk of Parkinson's disease in unipolar depression: A retrospective cohort study

Morrin H, Badenoch JB, Burchill E, Fayosse A, Singh-Manoux A, Shotbolt P, Zandi MS, David AS, Lewis G, Rogers JP.

J Affect Disord. 2026 Dec 1;414:122339. doi: 10.1016/j.jad.2026.122339. Epub 2026 Aug 7.

Perceived consequences and catastrophising help explain health-related quality of life in Parkinson's disease. A cross-sectional study

Azoidou V, Bhadra E, Camboe E, Dey KC, Zirra A, Rowsell K, Quah C, Budu C, Boyle T, Gallagher D, Bestwick JP, Smith LJ, Noyce AJ, Simonet C.

Parkinsonism Relat Disord. 2026 Sep;150:108421. doi: 10.1016/j.parkreldis.2026.108421. Epub 2026 Jul 10.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias